Literature DB >> 16884454

Chronic intraperitoneal injection of interferon-alpha reduces serotonin levels in various regions of rat brain, but does not change levels of serotonin transporter mRNA, nitrite or nitrate.

Taku Sato1, Eiji Suzuki, Masamoto Yokoyama, Jun'ichi Semba, Shigeru Watanabe, Hitoshi Miyaoka.   

Abstract

Interferon-alpha therapy is associated with a high rate of depression, but the pathophysiological mechanisms remain unclear. The purpose of the present study was to investigate the effects of i.p. administered interferon-alpha on monoaminergic neurotransmission in the brain. The levels of monoamines and associated metabolites were measured in various regions of the rat brain using a high-performance liquid chromatography-electrochemical detection system. The serotonin transporter mRNA levels were also measured using in situ hybridization. After 1 day, dopamine turnover was diminished in the cortex. Norepinephrine turnover was decreased in most regions tested after 4 days. However, these changes were transient. After 14 days, serotonin turnover was increased in the frontal cortex and hippocampus in rats given a dose of 20 000 IU/kg; in the frontal cortex, hippocampus, amygdala, thalamus, hypothalamus and brainstem in those on 200 000 IU/kg; and in the thalamus and hypothalamus in those on 2 000 000 IU/kg (all P < 0.05). However, 14-day treatment did not significantly change serotonin transporter mRNA levels. Next, the question of whether interferon-alpha affects monoamine levels via induction of nitric oxide (NO), was investigated. However, there were no changes in either NO2- or NO3-, as markers of NO production, in any brain regions after 14-day treatment. These results suggest that chronic peripheral administration of interferon-alpha induces metabolic changes in the central serotonin system. Further investigation is needed to determine exactly how this cytokine affects the central serotonin system and to assess whether a central serotonin abnormality is involved in interferon-induced depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884454     DOI: 10.1111/j.1440-1819.2006.01538.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  10 in total

Review 1.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

Review 2.  Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?

Authors:  Robert K McNamara; Francis E Lotrich
Journal:  Expert Rev Neurother       Date:  2012-09       Impact factor: 4.618

Review 3.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

Review 4.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

Review 5.  Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.

Authors:  Jennifer C Felger; Michael T Treadway
Journal:  Neuropsychopharmacology       Date:  2016-08-02       Impact factor: 7.853

6.  Mitigation of Inflammation-Induced Mood Dysregulation by Long-Chain Omega-3 Fatty Acids.

Authors:  Robert K McNamara
Journal:  J Am Coll Nutr       Date:  2015       Impact factor: 3.169

7.  Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma.

Authors:  Tarek Kamal Motawi; Noha Ahmed El-Boghdady; Abeer Mostafa El-Sayed; Hebatullah Samy Helmy
Journal:  Tumour Biol       Date:  2015-08-26

Review 8.  Imaging the Role of Inflammation in Mood and Anxiety-related Disorders.

Authors:  Jennifer C Felger
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

9.  Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy.

Authors:  Durk Fekkes; Arthur R Van Gool; Marjolein Bannink; Stefan Sleijfer; Wim H J Kruit; Bronno van der Holt; Alexander M M Eggermont; Michiel W Hengeveld; Gerrit Stoter
Journal:  Amino Acids       Date:  2008-10-26       Impact factor: 3.520

Review 10.  Brain Kynurenine and BH4 Pathways: Relevance to the Pathophysiology and Treatment of Inflammation-Driven Depressive Symptoms.

Authors:  Sylvie Vancassel; Lucile Capuron; Nathalie Castanon
Journal:  Front Neurosci       Date:  2018-07-24       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.